Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged &lt;6 Months — 17 States, July 2021–January 2022

Halasa, Natasha; Olson, Samantha M; Staat, Mary Allen; Newhams, Margaret M; Price, Ashley M; Boom, Julie A.; Sahni, Leila C; Cameron, Melissa A; Pannaraj, Pia S.; Bline, Katherine; Bhumbra, Samina; Bradford, Tamara T; Chiotos, Kathleen; Coates, Bria M.; Cullimore, Melissa L; Cvijanovich, Natalie Z.; Flori, Heidi R.; Gertz, Shira J.; Heidemann, Sabrina M.; Hobbs, Charlotte V.; Hume, Janet R.; Irby, Katherine; Kamidani, Satoshi; Kong, Michele; Levy, Emily R.; Mack, Elizabeth H.; Maddux, Aline B; Michelson, Kelly; Nofziger, Ryan A; Schuster, Jennifer E; Schwartz, Stephanie P; Smallcomb, Laura; Tarquinio, Keiko M.; Walker, Tracie C; Zinter, Matt S; Gilboa, Suzanne M.; Polen, Kara; Campbell, Angela P; Randolph, Adrienne G.; Patel, Manish; Zambrano, Laura D.; Murdock, Meghan; Gaspers, Mary Glas; Kelley, Connor P; Typpo, Katri; Mourani, Peter M.; Sanders, Ronald C.; Smith, Chelsea; Yates, Masson; Crane, Katheryn; Lionetti, Geraldina; Murcia-Montoya, Juliana; Villarreal-Chico, Denise; Hakimi, Daniel; Skura, Adam L.; Carson, Imogene; Lockwood, Justin; Port, Emily; Chatani, Brandon; Baida, Nadine; Hussaini, Laila; Khan, Hassan; Rhodes, Simone T.; Rowan, Courtney M.; Stumpf, Mary; Johnston, Marla S.; Berbert, Laura; Boutselis, Benjamin J; Chen, Sabrina R; He, Jie; Kucukak, Suden; McCadden, Timothy P; Orzel, Amber O; Weller, Edie; Moran, Patrick; Bruno, Ellen R.; Goertzen, Lexie A.; Behl, Supriya; Drapeau, Noelle M.; Malloch, Lacy; Martin, Lora; Palmer, April; Santos, Roberto; Kietzman, Abigail; Sullivan, Melissa; Hoody, Lauren A.; Rinehart, Valerie H.; Bennett, Paris C.; Tomcany, Merry L.; Twinem, Nicole A.; Rohlfs, Chelsea C.; Wolfe, Amber; Douglas, Rebecca L.; Phengchomphet, Kathlyn; Bickford, Megan M.; Wakefield, Lauren E; Golchha, Meena; Stewart, Laura S; Oates, Jennifer N.; Bowens, Cindy Darnell; Maamari, Mia

doi:10.15585/mmwr.mm7107e3

Cited by 173 publications

(162 citation statements)

References 10 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…Future studies are needed to understand the possible long-term consequences of COVID-19 infection among infants. Although infants aged <6 months are not currently eligible for vaccination, evidence suggests that this age group can receive protection through passive transplacental transfer of maternal antibodies acquired through vaccination ( 9 ). CDC recommends that women who are pregnant, breastfeeding, trying to become pregnant, or might become pregnant get vaccinated and stay up to date with COVID-19 vaccination.…”

Section: Discussionmentioning

confidence: 99%

Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022

Marks¹,

Whitaker²,

Agathis³

et al. 2022

MMWR Morb. Mortal. Wkly. Rep.

155

176

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022

Marks¹,

Whitaker²,

Agathis³

et al. 2022

MMWR Morb. Mortal. Wkly. Rep.

155

176

View full text Add to dashboard Cite

“…For these populations who are at highest risk of severe outcomes if infected with SARS-CoV-2, ongoing boosters remain a highly relevant and valuable strategy. We are also not capturing new birth cohorts into the model with near complete susceptibilty and no prior immunity to COVID beyond mother-to-child immune transference, for whom any vaccination strategy would be better than risking infection (30; 31). While our model has a robust mechanistic representation of immune dynamics, we do not capture the process of affinity maturation that antibodies go through over time and after repeated exposures to an antigen that increase the breadth of the immune response even in the face of waning (32).…”

Section: Discussionmentioning

confidence: 99%

The changing impact of vaccines in the COVID-19 pandemic

Cohen¹,

Stuart

Panovska‐Griffiths

et al. 2022

Preprint

View full text Add to dashboard Cite

The Omicron wave has left a global imprinting of immunity which changes the COVID landscape. In this study, we simulate six hypothetical variants emerging over the next year and evaluate the impact of existing and improved vaccines. We base our study on South Africa's infection- and vaccination-derived immunity. Our findings illustrate that variant-chasing vaccines will only add value above existing vaccines in the setting where a variant emerges if we can shorten the window between variant introduction and vaccine deployment to under three weeks, an impossible time-frame without significant NPI use. This strategy may have global utility, depending on the rate of spread from setting to setting. Broadly neutralizing and durable next-generation vaccines could avert over three-times as many deaths from an immune-evading variant compared to existing vaccines. Our results suggest it is crucial to develop next-generation vaccines and redress inequities in vaccine distribution to tackle future emerging variants.

show abstract

“…The risk of hospitalisation with acute COVID-19 among cases <1 year was lower in the Delta and Omicron waves, compared to the Alpha wave. As the majority of hospitalised cases <1 year across the three waves were <3 months old, the decrease in risk may be related to protection offered to infants born to mothers vaccinated during pregnancy (27). Vaccination during pregnancy was first generally recommended in Norway before the start of the Delta wave.…”

Section: Discussionmentioning

confidence: 99%

Severe outcomes in unvaccinated COVID-19 cases <18 years during different variant waves in Norway

Whittaker

Greve-Isdahl

Bøås

et al. 2022

Preprint

View full text Add to dashboard Cite

Objectives We used linked individual-level data from national registries to compare the risk of severe outcomes among unvaccinated COVID-19 cases <18 years between waves of the SARS-CoV-2 Alpha, Delta and Omicron variants in Norway. Methods Our outcomes were hospitalisation with acute COVID-19 or multisystem inflammatory syndrome in children (MIS-C). We calculated adjusted risk ratios (aRR) with 95% confidence intervals (CIs) using multivariable log-binomial regression, adjusting for variant wave, demographic characteristics and underlying comorbidities. Results We included 10,538 Alpha (21 hospitalised with acute COVID-19, 7 MIS-C), 42,362 Delta (28 acute COVID-19, 14 MIS-C) and 82,907 Omicron wave cases (48 acute COVID-19, 7 MIS-C). The risk of hospitalisation with acute COVID-19 in cases <1 year was lower in the Delta (aRR: 0.28, 95% CI: 0.16-0.89) and Omicron wave (aRR: 0.41, 95% CI: 0.20-0.81), compared to the Alpha wave. We found no difference in the risk for this outcome for Omicron compared to Delta in any age group. The risk of MIS-C was lower in the Omicron wave compared to the Alpha (aRR: 0.09, 95% CI: 0.03-0.27) and Delta wave (aRR: 0.26, 95% CI: 0.10-0.63). Conclusions We found no evidence of a difference in the risk of hospitalisation due to acute COVID-19 among unvaccinated cases <18 years for Omicron compared to Delta, but a reduced risk among cases <1 year in Omicron and Delta waves, compared to Alpha. Results also suggest a decrease in the risk of MIS-C in the Omicron wave compared to the Alpha and Delta waves.

show abstract

Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022

Cited by 173 publications

References 10 publications

Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022

Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022

The changing impact of vaccines in the COVID-19 pandemic

Severe outcomes in unvaccinated COVID-19 cases <18 years during different variant waves in Norway

Contact Info

Product

Resources

About